To include your compound in the COVID-19 Resource Center, submit it here.

Tyme shares tumble after pancreatic cancer data

Tyme Technologies Inc. (NASDAQ:TYME) lost $1.32 (35%) to $2.41 on Jan. 18 after the company reported preliminary data from the open-label Phase II Tyme-88-Panc trial. The company said that once-daily

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE